Literature DB >> 10450509

HLA class II transgenic mice as models of human diseases.

V Taneja1, C S David.   

Abstract

Predisposition to develop various autoimmune disorders has been associated with certain HLA class II molecules but there is a lack of information on the pathophysiological role of HLA genes in conferring susceptibility. Various experimental animal models of autoimmune disease have been studied to address the role of immune response genes. To study the interactions involved between class II molecules (DQ and DR) and define the immunologic mechanisms in various diseases, we generated HLA-DR and DQ transgenic mice that lacked endogenous class II molecules. The HLA molecules in these mice are expressed on the cell surface and can positively select CD4+ T cells expressing various V beta T-cell receptors (TCR). A peripheral tolerance is maintained to transgenic HLA molecules thus indicating that these molecules act as self. Mouse co-stimulatory and accessory molecules can interact with the HLA-peptide-TCR complex leading to efficient T-cell activation. In this review, we describe immunogenetic models for human diseases using these transgenic mice. Our studies show that HLA class II transgene-restricted T cells recognize the immunodominant antigens and peptide epitopes, similar to HLA class II-restricted human T cells. Thus these mice provide powerful tools to understand the role of HLA class II molecules in predisposition and onset of human diseases and to develop immunotherapy and vaccines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10450509     DOI: 10.1111/j.1600-065x.1999.tb01307.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  20 in total

Review 1.  Class II transactivator: mastering the art of major histocompatibility complex expression.

Authors:  J A Harton; J P Ting
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

Review 2.  Association of MHC and rheumatoid arthritis. Regulatory role of HLA class II molecules in animal models of RA: studies on transgenic/knockout mice.

Authors:  V Taneja; C S David
Journal:  Arthritis Res       Date:  2000-04-12

Review 3.  Genetic bases of autoimmune hepatitis.

Authors:  Albert J Czaja; Derek G Doherty; Peter T Donaldson
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

4.  An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.

Authors:  Richard F Jones; Joyce D Reyes; Heather M Gibson; Jennifer B Jacob; Ulka Vaishampayan; Stuart Ratner; Kang Chen; Wei-Zen Wei
Journal:  Cancer Immunol Immunother       Date:  2019-06-08       Impact factor: 6.968

Review 5.  A look at autoimmunity and inflammation in the eye.

Authors:  Rachel R Caspi
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

6.  Retinal self-antigen induces a predominantly Th1 effector response in Axl and Mertk double-knockout mice.

Authors:  Fei Ye; Lixia Han; Qingjun Lu; Wanwei Dong; Zhenwen Chen; Hui Shao; Henry J Kaplan; Qiutang Li; Qingxian Lu
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

Review 7.  HLA class II molecules influence susceptibility versus protection in inflammatory diseases by determining the cytokine profile.

Authors:  Ashutosh K Mangalam; Veena Taneja; Chella S David
Journal:  J Immunol       Date:  2013-01-15       Impact factor: 5.422

Review 8.  Immunopathogenesis of vasculitis.

Authors:  Raquel Cuchacovich
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

Review 9.  Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?

Authors:  Gargi Dasgupta; Lbachir BenMohamed
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

Review 10.  Mouse models of experimental autoimmune uveitis.

Authors:  Rachel R Caspi; Phyllis B Silver; Dror Luger; Jun Tang; Lizette M Cortes; Giuseppina Pennesi; Mary J Mattapallil; Chi-Chao Chan
Journal:  Ophthalmic Res       Date:  2008-04-18       Impact factor: 2.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.